Sirtex

Sirtex Medical Announces Collaboration Agreement with Magle Group for EmboCept® S DSM 50 μm

Retrieved on: 
Friday, September 8, 2023
DSM, Partnership, Marketing, Frederik Magle, Cancer, Lung cancer, Sale, Liver cancer, Death, Patient, Liver, National Institute for Health and Care Excellence, World Health Organization, Pharmaceutical industry, Medical imaging, Sirtex

WOBURN, Mass., Sept. 8, 2023 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the establishment of a collaboration and exclusive worldwide distribution agreement with Magle Group, a Sweden-based contract development and manufacturing organization as well as Degradable Starch Microspheres (DSM) sales and marketing company.

Key Points: 
  • Under the terms of the agreement, Sirtex will exclusively distribute Magle Group's chemoembolization product, EmboCept® S DSM 50 μm, in the existing and new geographic areas to support expanded patient access to the product.
  • Together, Sirtex and Magle also intend to establish a joint development plan to increase product range in the field of embolization by utilizing Magle Group's DSM platform.
  • Indicated for chemoembolization of liver and lung tumors, EmboCept® S DSM 50 μm is an adjuvant in the intra-arterial treatment of inoperable liver and lung tumors in combination with cytostatic agents.
  • EmboCept® S DSM 50 µm is currently approved for sale in Europe, Argentina, Singapore, and Malaysia.

Sirtex Medical Announces Collaboration Agreement with Magle Group for EmboCept® S DSM 50 μm

Retrieved on: 
Friday, September 8, 2023
DSM, Partnership, Marketing, Frederik Magle, Cancer, Lung cancer, Sale, Liver cancer, Death, Patient, Liver, National Institute for Health and Care Excellence, World Health Organization, Pharmaceutical industry, Medical imaging, Sirtex

WOBURN, Mass., Sept. 8, 2023 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the establishment of a collaboration and exclusive worldwide distribution agreement with Magle Group, a Sweden-based contract development and manufacturing organization as well as Degradable Starch Microspheres (DSM) sales and marketing company.

Key Points: 
  • Under the terms of the agreement, Sirtex will exclusively distribute Magle Group's chemoembolization product, EmboCept® S DSM 50 μm, in the existing and new geographic areas to support expanded patient access to the product.
  • Together, Sirtex and Magle also intend to establish a joint development plan to increase product range in the field of embolization by utilizing Magle Group's DSM platform.
  • Indicated for chemoembolization of liver and lung tumors, EmboCept® S DSM 50 μm is an adjuvant in the intra-arterial treatment of inoperable liver and lung tumors in combination with cytostatic agents.
  • EmboCept® S DSM 50 µm is currently approved for sale in Europe, Argentina, Singapore, and Malaysia.

DGAP-News: Eckert & Ziegler Extends Supply Agreement with Sirtex Medical to Chinese Market

Retrieved on: 
Friday, April 1, 2022
NICE, Nuclear medicine, TecDAX, Radiopharmaceutical, Liver, III, Growth, Mortality, II, Colorectal cancer, Y-90, News, DGAP, CMC, Deutsch, National Institute, Death, ISIN, SIRT, Liver cancer, Disease, Isotope, GMP, Partnership, Security (finance), Pharmaceutical industry, Sirtex

Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have extended their long-term supply agreement for the use of yttrium-90 in Sirtex microspheres for the treatment of liver cancer to the Chinese market.

Key Points: 
  • Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have extended their long-term supply agreement for the use of yttrium-90 in Sirtex microspheres for the treatment of liver cancer to the Chinese market.
  • From its production facilities in Braunschweig and Boston (MA), USA, Eckert & Ziegler supplies the Sirtex sites in Frankfurt, Boston, and Singapore with yttrium-90.
  • "The signing of this supply agreement reinforces the already strong relationship between the two companies as Sirtex enters the Chinese market", adds Grant Spindler, Global Head of Operations at Sirtex Medical Limited.
  • In Jintan (China), Eckert & Ziegler is investing up to EUR 50 million in the construction of a production facility for radiopharmaceuticals.

DGAP-News: Eckert & Ziegler Signs Long-Term Supply Agreement with Sirtex Medical on Yttrium-90 for Treating Liver Cancer

Retrieved on: 
Wednesday, April 28, 2021
Medicine, Physical sciences, Chemistry, SIR-Spheres, Radiation therapy, Sirtex, Yttrium, TecDAX, Eckert

Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have executed a long-term supply agreement for the use of EZAG\'s Yttrium-90 in Sirtex SIR-Spheres(R) Y-90 resin microspheres for liver cancer.

Key Points: 
  • Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have executed a long-term supply agreement for the use of EZAG\'s Yttrium-90 in Sirtex SIR-Spheres(R) Y-90 resin microspheres for liver cancer.
  • The arrangement has an initial term of five years and guarantees Eckert & Ziegler a substantial share of Sirtex\'s rising global demand.
  • It supplements the existing broad-based supply agreement that Sirtex and Eckert & Ziegler have been operating since 2009.
  • "\n"With its global manufacturing network, Eckert & Ziegler is an ideal partner for us to supply yttrium-90 worldwide.

Sirtex Medical and BlackSwan Vascular, Inc. announce first patient enrolled in pivotal LAVA Study

Retrieved on: 
Monday, April 19, 2021
Radiation therapy, Sirtex, Liver, Interventional radiology

"\nLAVA is led by co-principal investigators Dr. Bulent Arslan at the Rush University Medical Center in Chicago and Dr. Mahmood Razavi at St. Joseph Heart and Vascular Center in Orange, California.

Key Points: 
  • "\nLAVA is led by co-principal investigators Dr. Bulent Arslan at the Rush University Medical Center in Chicago and Dr. Mahmood Razavi at St. Joseph Heart and Vascular Center in Orange, California.
  • "Moving the LAVA Study forward advances our mission to provide the interventional community with the tools they need that drive safe, effective and value-based treatments.
  • "\nThe LAVA Study enrollment follows the strategic collaboration Sirtex and BlackSwan entered in December 2020.
  • More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,400 medical centers in over 50 countries.

Sirtex Medical and BlackSwan Vascular, Inc. announce first patient enrolled in pivotal LAVA Study

Retrieved on: 
Monday, April 19, 2021
Radiation therapy, Sirtex, SIR-Spheres, Liver

"Moving the LAVA Study forward advances our mission to provide the interventional community with the tools they need that drive safe, effective and value-based treatments.

Key Points: 
  • "Moving the LAVA Study forward advances our mission to provide the interventional community with the tools they need that drive safe, effective and value-based treatments.
  • "\nThe LAVA Study enrollment follows the strategic collaboration Sirtex and BlackSwan entered in December 2020.
  • More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,400 medical centers in over 50 countries.
  • SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/sirtex-medical-and-blackswan-vas...\n'

SteriPack Appoints Andrew McLean as President & CEO

Retrieved on: 
Thursday, February 4, 2021
Health sciences, Companies, Health care, Synergy Health, Sirtex, Pfizer, Pharmaceutical industry, Steris

LAKELAND, Fla., Feb. 4, 2021 /PRNewswire/ --SteriPack Group ("SteriPack"), a leading global contract manufacturer of medical, consumer healthcare, diagnostic, pharmaceutical and combination devices, announced today that Andrew McLean has been named the company's President & CEO.

Key Points: 
  • LAKELAND, Fla., Feb. 4, 2021 /PRNewswire/ --SteriPack Group ("SteriPack"), a leading global contract manufacturer of medical, consumer healthcare, diagnostic, pharmaceutical and combination devices, announced today that Andrew McLean has been named the company's President & CEO.
  • Andrew McLean brings more than 20 years of medical device and pharmaceutical expertise to SteriPack, with prior leadership roles at Pfizer, BD, Synergy Health, Steris Corp and more recently CEO at Sirtex Medical.
  • Andrew McLean said, "SteriPack is a highly responsive contract manufacturer providing integrated product lifecycle management solutions.
  • This company truly is a team of wonderful, talented individuals, and I am thrilled to be joining SteriPack."

Global Liver Cancer Therapeutics Market to 2025 by Cancer Type, Therapy, Equipment, Age, Factors, Route of Administration, Distribution Channel, Region, Competition, Forecast & Opportunities

Retrieved on: 
Thursday, January 21, 2021
Clinical medicine, Medicine, Cancer, Oncology, Hepatology, Chemotherapy, Liver cancer, War on Cancer, Sirtex

According to World Cancer Research Fund, liver cancer is the sixth most common cancer across the globe.

Key Points: 
  • According to World Cancer Research Fund, liver cancer is the sixth most common cancer across the globe.
  • Expensive treatments as well as high cost in research and development might hamper further development of liver cancer therapeutics market.
  • The Global Liver Cancer Therapeutics Market is segmented based on cancer type, therapy, equipment, age, factors, route of administration, distribution channel and region.
  • The oral segment is anticipated to dominate the Global Liver Cancer Therapeutics Market during the forecast period as it is most preferred route of administration for chemotherapy.

Sirtex Medical announces collaboration update with OncoSec Medical

Retrieved on: 
Tuesday, January 19, 2021
Life sciences, Biology, Biotechnology, Radiation therapy, Sirtex, Food and Drug Administration, Biopharmaceutical, Electroporation, Biologics license application

WOBURN, Mass., Jan. 19, 2021 /PRNewswire/ -- Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec's lead product candidate TAVO (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.

Key Points: 
  • WOBURN, Mass., Jan. 19, 2021 /PRNewswire/ -- Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec's lead product candidate TAVO (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.
  • Sirtex has the right to exercise the option until 90 days following the filing of a Biologics License Application (BLA) by OncoSec.
  • "We are thrilled to advance our partnership with OncoSec as the clinical development of TAVO progresses," said Kevin R. Smith, Chief Executive Officer of Sirtex.
  • "Our collaboration with Sirtex is a natural fit given our common mission to deliver more effective therapies to patients," said Daniel J. O'Connor, CEO of OncoSec.

Sirtex Medical announces collaboration update with OncoSec Medical

Retrieved on: 
Tuesday, January 19, 2021
Life sciences, Biology, Biotechnology, Radiation therapy, Sirtex, Food and Drug Administration, Biopharmaceutical, Electroporation, Biologics license application

WOBURN, Massachusetts, Jan. 19, 2021 /PRNewswire/ -- Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec's lead product candidate TAVO (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.

Key Points: 
  • WOBURN, Massachusetts, Jan. 19, 2021 /PRNewswire/ -- Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec's lead product candidate TAVO (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.
  • Sirtex has the right to exercise the option until 90 days following the filing of a Biologics License Application (BLA) by OncoSec.
  • "We are thrilled to advance our partnership with OncoSec as the clinical development of TAVO progresses," said Kevin R. Smith, Chief Executive Officer of Sirtex.
  • "Our collaboration with Sirtex is a natural fit given our common mission to deliver more effective therapies to patients," said Daniel J. O'Connor, CEO of OncoSec.